

The Rise of ADC's in Gynecologic Cancer: Transitioning from Research to Practice

Resort at Squaw Creek

Olympic Valley, California

Friday, January 28, 2022

**OUR PROGRAM
WILL BEGIN SOON**

A GOG Foundation, Inc. Educational Program

The Rise of ADC's in Gynecologic Cancer: Transitioning from Research to Practice

Resort at Squaw Creek

Olympic Valley, California

Friday, January 28, 2022

A GOG Foundation, Inc. Educational Program

LEARNING OBJECTIVES

THE OVERALL OBJECTIVE OF THIS SYMPOSIA IS TO INCREASE CLINICIANS' KNOWLEDGE AND COMPETENCE REGARDING THE VARIOUS TARGETED ANTIBODY DRUG CONJUGATES AVAILABLE. LEARNERS WILL ALSO UNDERSTAND HOW TO BEST INCORPORATE THESE ADVANCED TREATMENTS INTO CLINICAL PRACTICE.

Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding

- Understanding targeted drug therapy as a treatment option for patients with ovarian and cervical cancer;
- Increased knowledge regarding advanced treatments available for ovarian and cervical cancer;
- Identify adverse events and understand management to facilitate therapy;
- Learn how to best implement treatment into practice to improve patient outcomes.

GOG FACULTY DISCLOSURE INFORMATION

Symposium, “The Rise of ADC’s in Gynecologic Cancer: Transitioning from Research to Practice”

JANUARY 28, 2022

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). All **Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations.**

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within **the past 24 months** that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “**ineligible company**” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

GOG FACULTY DISCLOSURE INFORMATION

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any **ineligible company** *(formally known as commercial interests). **All Committee/Planning/Faculty members** were required to disclose all financial relationships and speakers were required to disclose any financial relationship **as it pertains to the content of the presentations.**

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “**ineligible company**” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

NAME	Individual's Role(s) in Activity	Nothing To Disclose	DISCLOSURE <company & role>
<i>Speaker/Moderators</i>			
Ramez Eskander, MD	Planning/Speaker		Advisory Board/Consulting Fee/Speaking: AstraZeneca; Merck; Clovis; GSK, Myriad
Thomas Herzog, MD	Planning/Speaker	x	
Kathleen Moore, MD	Speaker		Advisory board: AstraZeneca, Aravive, Blueprint, Alkermes, OnxXema, Eisai, GSK, Elevar, Genentech, Immunogen, Merck, VBL, Mersana, Myriad
David O'Malley, MD	Speaker		Honorarium: Roche Diagnostics, Watermark, Immunogen, AstraZeneca, Sorrento, Rubius, Elevar, Novartis, Eisai, GSK, Novocure, Genentech, GOG Foundation, Mersana, Seattle Genetics, Ambry, Regeneron, Myriad, GSK/Tesaro, Agenus
Bhavana Pothuri, MD	Speaker		Research funding support/ Ad Board fees: AstraZeneca, Celsion, Immunogen, Merck, Mersana, Seattle Genetics, Sutro, Takada, Tesaro, Clovis Oncology Advisory Board: Eisai, Lily, GOG Foundation
Leslie Randall, MD	Speaker		Consulting fee: Agenus, Clovis, Myriad, Mersana, GSK/Tesaro Research Grant/ Contractor: Merck, Pfizer
Michelle Small	Staff	x	
Jill Reese	Staff	x	

GOG CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™

The GOG Foundation, Inc. designates this internet live activity for a maximum of 1.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.

COMMERCIAL SUPPORTERS

The GOG Foundation, Inc. and GOG Partners would like to thank our commercial supporters for their unrestricted educational grants associated with this Symposium: *ImmunoGen, Mersana, Genmab and Seagen Inc.*

FACULTY



Ramez Eskander, MD, UC San Diego, Moores Comprehensive Cancer Center, San Diego, California, USA

Thomas J. Herzog, MD, University of Cincinnati, Cincinnati, Ohio, USA

Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA

David O'Malley, MD, The Ohio State University, James Cancer Center, Columbus, Ohio, USA

Bhavana Pothuri, MD, NYU Langone, New York City, New York, USA

Leslie Randall, MD, Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia, USA

THANK YOU

View this symposium on-demand at GOG.org
or the GOG YouTube channel